Skip to content
ContentLora

    Tip: press / anywhere to search.

    ● Developing story

    Synthetic biology tracker: milestones and policy

    This tracker follows verifiable milestones in synthetic biology and biomanufacturing: genome writing, circuit design methods, DNA synthesis capacity, fermentation plants and screening policy.[1][2][3] As of October 2026 the biggest open items are the pending replacement of the 2024 US nucleic acid synthesis screening framework and whether new pilot plants fill.[4][5]

    Editor reviewedUpdated Synthetic biologyLife sciencesTech policy

    What we know

    • The Sc2.0 chromosome set was completed with the 903 kb synXVI in January 2025[6]
    • A 4 Mb Escherichia coli genome with more than 101,000 codon changes was published in 2025 as Syn57[1]
    • Circuit design can now be measured across hundreds of thousands to millions of variants in one experiment[2]
    • US screening rules run through federal research funding and cover benchtop devices[12]
    • Agencies were ordered in May 2025 to revise or replace the 2024 screening framework; no replacement has been published[4]
    • BioMADE's first demonstration plant has two 25,000-litre fermenters and cost $132 million[3]
    • Gene shipments from one major provider rose from about 237,000 to about 369,000 per quarter year on year[25]
    • Ginkgo Bioworks cut more than half its workforce and divested biosecurity, leaving a $20.2 million quarter[10]
    • A DNA synthesis provider was used as an independent evaluator for AI-designed proteins in August 2026[22]
    • Mammalian pathway engineering now screens millions of combinations in one experiment[21]

    What we don't know yet

    • What the revised US nucleic acid synthesis screening framework will require, and when it will be published
    • Whether the new US pilot and demonstration plants will be fully utilised, since booking and throughput data are not published
    • How screening performance compares across synthesis providers, given only interview-based evidence of variation
    • Whether all Sc2.0 synthetic chromosomes have been consolidated and characterised in a single strain
    • Whether AI-assisted circuit design transfers from human cell lines to industrial production hosts
    • Whether AI-designed protein binders reported at 22 to 35 percent hit rates reproduce outside the designing company's own campaign
    • When BioMADE's Iowa pilot plant will open: its own releases have given both 2027 and early 2028
    Story status

    Story status

    State
    developing
    Started
    2010-01-01
    Timeline entries
    23
    Last entry

    Timeline data (JSON)

    Where the field stands

    Three threads move at different speeds. Genome writing has delivered finished artefacts: a completed synthetic yeast chromosome set and a recoded four-megabase bacterial genome.[6][1] Design methodology changed in early 2026, when very large measured libraries plus machine learning replaced hand-tuning for genetic circuits.[2][7] Industrial capacity is the slowest thread, and the one now absorbing public money.[3][8]

    The commercial split is stark. Input suppliers grew: Twist Bioscience reported record revenue of $118.4 million in the quarter to June 2026.[9] Organism-engineering services shrank: Ginkgo Bioworks reported $20.2 million with government and defence customers supplying 45% of revenue.[10][11]

    What to watch next

    The clearest near-term signal is governance: the replacement for the 2024 US synthesis screening framework ordered in May 2025 has not appeared, and its scope will determine whether screening remains a funding condition or becomes something broader.[4][12]

    On capacity, watch opening dates and utilisation at BioMADE‘s sites: BioMADE aimed to open the Hayward pilot plant to customers in early 2026, and its published Iowa date has moved between 2027 and early 2028.[5][13] On products, further GRAS outcomes after the September 2025 fermented egg protein letter will show whether the regulatory path is repeatable.[14]

    On technology, two things would count as real progress: construct lengths beyond today’s 50-kilobase commercial ceiling, and evidence that AI-assisted circuit design transfers from human cell lines into production hosts.[15][16][17] Cell-free routes are worth watching through public funding, including the August 2026 ARPA-H award for cell-free DNA bioproduction.[18]

    Design and measurement

    Two 2026 results changed what counts as a design method. In January, high-throughput mapping measured hundreds of thousands to millions of genetic circuit designs in one experiment, and models trained on those measurements predicted untested variants; all 40 designs checked by hand matched.[2][7] In October, Nature Biotechnology published Shotgun Genetic Engineering, which delivers many barcoded small constructs into mammalian cells instead of one large construct, so each cell tests a different pathway and working combinations are found by sequencing barcodes.[19][20] Its authors screened millions of combinations in CHO and Jurkat cells, reached near-wild-type growth in valine-free medium and, they say for the first time, isoleucine prototrophy in CHO cells, with working solutions needing 23 to 52 kilobases of synthetic DNA.[21] That length requirement ties design throughput back to synthesis capacity.[15]

    Protein design is being pulled into the same loop. On 18 August 2026 Twist Bioscience disclosed in an SEC filing that anthropic had chosen it as one of the independent evaluators to make and test proteins its models had designed against 15 targets.[22] Anthropic reported binders against 14 of the 15 targets, with hit rates of 22.6 to 35.1 percent against the 10 to 15 percent it says is typical, using up to 12,500 NVIDIA H100 hours per run.[23][24] These are the model developer’s own figures, published alongside the filing rather than in a peer-reviewed paper, so they are recorded here as reported. Disclosure: Anthropic also provides the model used to draft pages on this site.

    Why these entries

    The timeline mixes three kinds of event on purpose, because the field advances unevenly. Published results date the science: a completed synthetic chromosome set, a recoded bacterial genome, a new way to measure circuit designs.[6][1][2] Filings and company announcements date the industry, including quarterly DNA volumes and the restructuring of the best-known cell engineering company.[25][26] Government actions date the rules and the money, from the screening framework to pilot-plant investment.[27][3]

    How this tracker is maintained

    Entries are added only with a dated source and are tagged confirmed, reported, disputed or unknown. The modern era here is dated from around 2010, when US screening guidance for providers and users of synthetic nucleic acids was first issued and synthetic genomes began to be installed in cells.[28] Official feeds for this field are listed in the pipeline configuration so new milestones surface automatically.[29]

    Timeline

    20 confirmed3 reported

    1. confirmed

      Replacement screening framework still not published[4]

      US government pages continue to say they will be updated once the revised framework is available.

    2. confirmed

      Shotgun engineering screens millions of mammalian pathway combinations[19][20][21]

      Nature Biotechnology published the method, which delivers many barcoded small constructs instead of one large one and reads out working pathways by sequencing barcodes.

    3. reported

      A DNA synthesis provider validates AI-designed proteins[22][23][24]

      Twist Bioscience disclosed in an SEC filing that Anthropic had used it as one of two independent evaluators; the hit rates are the model developer's own figures.

    4. confirmed

      Record quarter for synthetic DNA, weak quarter for cell engineering services[9][25][10][11]

      Twist Bioscience reported $118.4 million and about 369,000 genes shipped; Ginkgo Bioworks reported $20.2 million with government and defence at 45% of revenue.

    5. confirmed

      ARPA-H funds cell-free DNA bioproduction[18]

      Up to $26 million to DNA Script and GE HealthCare for faster, distributed DNA manufacturing.

    6. reported

      Reporting details the US bioindustrial pilot plant build-out[8][5][47]

      Three plants, with Hayward opening first; BioMADE's own releases give the site sizes, tank volumes and target dates.

    7. confirmed

      Ginkgo Bioworks divests its biosecurity business[44]

      Dated to April 2026 in the company's filing; it now reports a single segment covering biological research services and tools.

    8. confirmed

      Defence and NSF fund 14 bioengineering research projects[45][46]

      BioMADE put the shared investment at over $21 million across 23 member organisations; press reporting gave $21.4 million across 14 projects.

    9. confirmed

      Benchtop DNA synthesis distribution widens[43]

      DNA Script added distributors in Latin America and East Asia, and in July 2026 in India.

    10. confirmed

      High-throughput mapping brings machine learning to circuit design[2][7][17]

      The CLASSIC method measured very large design libraries in human cells; models then predicted untested variants, with 40 of 40 hand-checked designs matching.

    11. confirmed

      Ginkgo Bioworks restructuring substantially concluded[26]

      Workforce reductions of more than 50% finished, with facility consolidation continuing through 2026.

    12. confirmed

      Groundbreaking for BioMADE's Iowa pilot plant[41][13][42]

      A 15,000-square-foot site near Ames with 5,000 and 10,000-litre fermenters in a $40 million project; the release said 2027, an earlier one said early 2028.

    13. confirmed

      Peer-reviewed analysis documents screening implementation gaps[38][39][40]

      Ambiguous definitions, fragmented triggers and thin institutional capacity, with most biosafety offices under three full-time staff.

    14. reported

      Enzymatic provider markets 50 kb clonal DNA[15][37]

      Ansa Biotechnologies announced constructs up to 50 kilobases from about 28 cents per base pair; the length comparison is a company claim.

    15. confirmed

      FDA raises no questions on fermented egg protein[14][36]

      Onego Bio's Bioalbumen ovalbumin, made in Trichoderma reesei, cleared GRAS notification as GRN 1249.

    16. confirmed

      Syn57 recoded Escherichia coli published in Science[1][35]

      A four-megabase synthetic genome with more than 101,000 codon changes, removing seven codons from the genetic code.

    17. confirmed

      Minimal cell workshop proceedings published[29][34]

      More than 90 research groups have worked with the JCVI minimal cell, which still contains unannotated genes the cell needs for normal growth.

    18. confirmed

      Executive order directs revision of the screening framework[4]

      The order on improving the safety and security of biological research told agencies to revise or replace the 2024 framework.

    19. confirmed

      BioMADE and Lygos fast-track a California pilot plant[5]

      A nearly 25,000-square-foot Hayward site with tanks up to 4,000 litres, in a project worth at least $80 million, aimed at opening to customers in early 2026.

    20. confirmed

      BioMADE finalises $132 million demonstration plant in Minnesota[3][33]

      A 122,000-square-foot site in Maple Grove with two 25,000-litre industrial fermenters, funded by the Department of Defense and the state.

    21. confirmed

      Congressional biotechnology commission delivers final report[31][32]

      Delivered in April 2025 with 49 recommendations, headlined by a call for at least $15 billion of US investment in biotechnology and biomanufacturing.

    22. confirmed

      Final Sc2.0 synthetic yeast chromosome reported[6][30]

      The 903-kilobase synXVI was published in Nature Communications, completing the project's chromosome set after iterative redesign.

    23. confirmed

      US framework for nucleic acid synthesis screening released[27][12]

      Screening compliance became a condition of federal life-sciences research funding, covering providers and benchtop synthesis devices.

    Sources

    Each numbered claim is a statement we checked against the sources listed with it. Status shows how well established it is.

    1. [1]

      Syn57 is an Escherichia coli strain whose 4-megabase genome was built by total synthesis with more than 101,000 codon changes, giving it a 57-codon genetic code; the work was published in Science in 2025. confirmedas of 2025-08-01

    2. [2]

      On 14 January 2026 a Rice University-led team reported CLASSIC in Nature, a method that combines long-read and short-read sequencing to measure hundreds of thousands to millions of genetic circuit designs in one experiment. confirmedas of 2026-01-14

    3. [3]

      On 29 April 2025 BioMADE finalised a $132 million investment, funded by the US Department of Defense and Minnesota's economic development department, in a 122,000-square-foot demonstration-scale biomanufacturing facility in Maple Grove, Minnesota with two 25,000-litre industrial fermenters. confirmedas of 2025-04-29

    4. [4]

      Under the executive order "Improving the Safety and Security of Biological Research" of 5 May 2025, federal agencies are to revise or replace the 2024 framework, and as of October 2026 the responsible US government page says it will be updated once the revised framework is available. confirmedas of 2026-10-10

    5. [5]

      BioMADE's California pilot plant in Hayward is a nearly 25,000-square-foot multi-user facility with aerated stirred tanks of up to 4,000 litres, in a project worth at least $80 million funded by the US Department of Defense; BioMADE said in April 2025 that it aimed to open it to customers in early 2026. confirmedas of 2025-04-30

    6. [6]

      The final synthetic chromosome of the Sc2.0 project, the 903-kilobase synXVI, was reported in Nature Communications on 20 January 2025. confirmedas of 2025-01-22

    7. [7]

      Machine-learning models trained on CLASSIC measurements predicted the behaviour of untested genetic circuit variants, and all 40 designs the team checked by hand matched the prediction. reportedas of 2026-01-14

    8. [8]

      The United States is reported to be severely short of pilot- and demonstration-scale equipment for precision fermentation, which is the stated reason for federal investment in bioindustrial pilot plants. reportedas of 2026-05-11

    9. [9]

      Twist Bioscience reported record revenue of $118.4 million for the third quarter of fiscal 2026, more than 23% above the $96.1 million of the same quarter a year earlier. confirmedas of 2026-08-05

    10. [10]

      Ginkgo Bioworks reported total revenue of $20.2 million and a net loss of $46.7 million for the quarter ended 30 June 2026. confirmedas of 2026-06-30

    11. [11]

      Government and defence customers accounted for 45% of Ginkgo Bioworks' revenue in the second quarter of 2026 and 41% in the first half, its largest customer group. confirmedas of 2026-06-30

    12. [12]

      The 2024 framework makes it a condition of US federal life-sciences research funding that synthetic nucleic acids, and benchtop devices that can make them, are bought only from providers and manufacturers that comply with the framework. confirmedas of 2026-10-10

    13. [13]

      BioMADE's stated opening date for the Iowa pilot plant has moved. An August 2025 release said the site was set to open in early 2028, while the November 2025 groundbreaking release said it was scheduled to open in 2027. disputedas of 2025-11-14

    14. [14]

      On 24 September 2025 Onego Bio said the US Food and Drug Administration had issued a "no questions" letter on the GRAS status of its Bioalbumen egg protein, filed as GRAS Notice GRN 1249. confirmedas of 2025-09-24

    15. [15]

      Ansa Biotechnologies announced commercial availability of clonal DNA constructs up to 50 kilobases made on its enzymatic DNA synthesis platform, roughly 100 times longer than its first product. reportedas of 2025-10-01

    16. [16]

      The CLASSIC libraries were built as genetic circuits and inserted into human embryonic kidney cells for measurement. confirmedas of 2026-01-14

    17. [17]

      The CLASSIC study found that many different part combinations can produce the same circuit function and that medium-strength components often outperform the strongest or weakest ones. reportedas of 2026-01-14

    18. [18]

      On 4 August 2026 DNA Script said it and GE HealthCare had been awarded up to $26 million by ARPA-H to advance cell-free DNA bioproduction under the FLASH programme. confirmedas of 2026-08-04

    19. [19]

      Nature Biotechnology published "Highly multiplexed mammalian metabolic engineering with a shotgun approach" on 6 October 2026. confirmedas of 2026-10-06

    20. [20]

      Shotgun Genetic Engineering delivers many barcoded small DNA constructs into mammalian cells rather than one large construct, so each cell carries a different synthetic pathway and functional combinations are identified by sequencing barcodes from cells with the wanted phenotype. confirmedas of 2025-07-08

    21. [21]

      The shotgun engineering authors screened millions of pathway combinations in CHO and Jurkat cells, reaching near-wild-type growth in valine-free medium and isoleucine prototrophy in CHO cells, with successful solutions requiring 23 to 52 kilobases of synthetic DNA. confirmedas of 2025-07-08

    22. [22]

      Twist Bioscience disclosed in an 18 August 2026 SEC filing that Anthropic had chosen it as one of the independent evaluators to produce at scale and test the binding of proteins designed by Anthropic's models in a campaign against 15 targets. confirmedas of 2026-08-18

    23. [23]

      Anthropic reported that its models designed binders against 14 of 15 protein targets, with overall hit rates of 26.7 percent and 22.6 percent in a multi-target setting and 35.1 percent when designing against each target separately, compared with the 10 to 15 percent it says is typical in protein design campaigns today. reportedas of 2026-08-18

    24. [24]

      Anthropic said each multi-target design run used 48 hours of wall time and up to 12,500 NVIDIA H100 hours of compute for specialised protein design and folding models, with 30 binders requested per target. reportedas of 2026-08-18

    25. [25]

      Twist Bioscience shipped about 369,000 synthetic genes in the third quarter of fiscal 2026, against about 237,000 in the same quarter of fiscal 2025. confirmedas of 2026-08-05

    26. [26]

      Ginkgo Bioworks cut more than half its workforce in a restructuring that was substantially concluded by 31 December 2025, with facility consolidation continuing through 2026. confirmedas of 2026-06-30

    27. [27]

      The White House Office of Science and Technology Policy released its Framework for Nucleic Acid Synthesis Screening on 29 April 2024. confirmedas of 2026-10-10

    28. [28]

      US screening guidance for providers and users of synthetic nucleic acids was first issued in 2010 and updated in later versions, including a 2023 update. confirmedas of 2026-10-10

    29. [29]

      More than 90 research groups have used or studied the JCVI minimal cell and related strains since the 2016 publication. confirmedas of 2025-06-02

    30. [30]

      The Sc2.0 team used a CRISPR-based debugging protocol, D-BUGS, to locate and correct design errors in synthetic chromosomes that impaired yeast growth. confirmedas of 2025-01-22

    31. [31]

      The National Security Commission on Emerging Biotechnology, a bipartisan body created by the fiscal 2022 National Defense Authorization Act, delivered its final report "Charting the Future of Biotechnology" to Congress in April 2025 with 49 recommendations. confirmedas of 2025-04-30

    32. [32]

      The commission's headline recommendation is at least $15 billion of US government investment to grow biotechnology innovation and biomanufacturing. confirmedas of 2025-04-30

    33. [33]

      BioMADE says the shortage of pilot- to demonstration-scale capacity forces American companies to use facilities overseas, taking innovation with them and risking loss of intellectual property. confirmedas of 2025-04-29

    34. [34]

      Some minimal-cell genes remain poorly understood, including an unannotated transaldolase that the cell needs to reach a two-hour doubling time. confirmedas of 2025-06-02

    35. [35]

      Syn57 removes seven codons from the genetic code: four that encode serine, two that encode alanine and one stop codon. confirmedas of 2025-08-01

    36. [36]

      Onego Bio's Bioalbumen is ovalbumin with the same amino acid sequence as chicken egg white protein, made by precision fermentation in the filamentous fungus Trichoderma reesei. confirmedas of 2025-09-24

    37. [37]

      Ansa Biotechnologies listed its long clonal DNA from as little as 28 cents per base pair with turnaround under 25 business days. reportedas of 2025-10-01

    38. [38]

      A 2025 peer-reviewed analysis identified three obstacles to effective sequence-level governance: ambiguous definitions of sequences of concern, fragmented regulatory triggers, and underdeveloped institutional capacity. confirmedas of 2025-10-28

    39. [39]

      The same analysis reports that most institutional biosafety offices operate with fewer than three full-time professional staff while handling committee reviews, incident response and training. confirmedas of 2025-10-28

    40. [40]

      The analysis cites interview research finding substantial variation between synthesis providers in screening sensitivity, treatment of short oligonucleotides, and monitoring and evaluation. confirmedas of 2025-10-28

    41. [41]

      BioMADE's Iowa pilot plant, built near Ames with Iowa State University, is a 15,000-square-foot multi-user site with 5,000 and 10,000-litre industrial fermenters, in a $40 million project to which BioMADE committed at least $20 million, matched by up to $10 million from the university and $10 million from a state infrastructure programme. confirmedas of 2025-11-14

    42. [42]

      BioMADE said in November 2025 that its network had passed 325 members across 40 states, and that it was catalysed by the US Department of Defense in October 2020 as a member of Manufacturing USA. confirmedas of 2025-11-14

    43. [43]

      DNA Script expanded distribution of on-demand DNA synthesis to Latin America and East Asia in March 2026 and to India in July 2026. confirmedas of 2026-07-16

    44. [44]

      After divesting its biosecurity business in April 2026, Ginkgo Bioworks reports as a single segment covering biological research services and tools. confirmedas of 2026-06-30

    45. [45]

      BioMADE said on 29 April 2026 that 14 new projects represented a shared investment of over $21 million across 23 member organisations, with federal money from the US Department of War and the National Science Foundation alongside non-federal cost share. confirmedas of 2026-04-29

    46. [46]

      In April 2026 the US Department of Defense and the National Science Foundation directed $21.4 million to 14 bioengineering research projects. reportedas of 2026-05-11

    47. [47]

      The US Department of Defense gave BioMADE about $87 million at its inception and directed a further $450 million to it in 2023. reportedas of 2026-05-11

    Revision history (2)
    1. Page created.
    2. Refresh: re-sourced the BioMADE pilot plants to the institute's own releases (superseding the May 2026 press summary), added the Hayward and Iowa entries, the April 2026 project awards, the August 2026 AI-designed-protein validation and the October 2026 shotgun engineering paper.

    Created Oct 10, 2026. Last reviewed by an editor on Oct 10, 2026. Next scheduled review: Jan 10, 2027.

    Cite this page

    "Synthetic biology tracker: milestones and policy." ContentLora, updated Oct 10, 2026. https://contentlora.com/events/synthetic-biology-tracker

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Keep exploring

    ☰ Contents